Amgen (MEX:AMG N) Cyclically Adjusted Revenue per Share: MXN973.17 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:AMG N Amgen Inc MEX:AMG N
86 GF Score
Price MXN6,349.00
GF Value MXN6,234.06
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Amgen Cyclically Adjusted Revenue per Share?

Amgen MEX:AMG N 86 Cyclically Adjusted Revenue per Share is MXN973.17 as of Mar. 2026. GuruFocus rates MEX:AMG N with a GF Score™ of 86/100 and a GF Value™ of MXN6,234.06 (Fairly Valued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Amgen's adjusted revenue per share for the three months ended in Mar. 2026 was MXN285.672. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN973.17 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Amgen's average Cyclically Adjusted Revenue Growth Rate was 9.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 8.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 10.40% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 10.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Amgen was 23.00% per year. The lowest was 8.70% per year. And the median was 14.20% per year.

As of today (2026-07-19), Amgen's current stock price is MXN6349.00. Amgen's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was MXN973.17. Amgen's Cyclically Adjusted PS Ratio of today is 6.52.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Amgen was 8.61. The lowest was 5.09. And the median was 6.91.


Amgen  (MEX:AMG N) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Amgen's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=6349.00/973.17
=6.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Amgen was 8.61. The lowest was 5.09. And the median was 6.91.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Amgen Cyclically Adjusted Revenue per Share Related Terms


Amgen Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Amgen's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amgen Cyclically Adjusted Revenue per Share Chart

Amgen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 763.05 795.25 750.48 988.74 953.60

Amgen Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,023.89 950.22 955.31 953.60 973.17

MEX:AMG N vs GILD, PFE, BMY: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, Amgen's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amgen Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amgen's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Amgen's Cyclically Adjusted PS Ratio falls into.


MEX:AMG N
86GF Score
Amgen Inc MEX:AMG N
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amgen Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Amgen's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=285.672/330.2130*330.2130
=285.672

Current CPI (Mar. 2026) = 330.2130.

Amgen Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 139.142 241.018 190.635
201609 149.215 241.428 204.089
201612 165.742 241.432 226.690
201703 138.842 243.801 188.053
201706 142.306 244.955 191.836
201709 142.931 246.819 191.224
201712 156.954 246.524 210.236
201803 141.917 249.554 187.786
201806 180.388 251.989 236.385
201809 170.161 252.439 222.586
201812 190.836 251.233 250.829
201903 172.196 254.202 223.686
201906 184.878 256.143 238.340
201909 188.139 256.759 241.962
201912 195.771 256.974 251.567
202003 243.204 258.115 311.137
202006 241.972 257.797 309.943
202009 240.901 260.280 305.627
202012 225.965 260.474 286.465
202103 207.612 264.877 258.823
202106 225.532 271.696 274.106
202109 241.910 274.310 291.210
202112 249.005 278.802 294.921
202203 225.417 287.504 258.903
202206 247.036 296.311 275.300
202209 248.708 296.808 276.699
202212 247.831 296.797 275.734
202303 204.540 301.836 223.770
202306 223.030 305.109 241.381
202309 223.499 307.789 239.782
202312 258.589 306.746 278.372
202403 230.583 312.332 243.784
202406 284.046 314.175 298.546
202409 308.905 315.301 323.515
202412 350.268 315.605 366.480
202503 308.159 319.799 318.194
202506 319.470 322.561 327.049
202509 323.460 324.800 328.851
202512 327.757 324.054 333.986
202603 285.672 330.213 285.672

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of MXN973.17 mean?
Amgen (MEX:AMG N) has a Cyclically Adjusted Revenue per Share of MXN973.17 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Amgen and its competitors.
Is Amgen's Cyclically Adjusted Revenue per Share too high?
Amgen's current Cyclically Adjusted Revenue per Share is MXN973.17. Overall, Amgen has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Amgen's Cyclically Adjusted Revenue per Share compare to GILD and PFE?
Amgen's Cyclically Adjusted Revenue per Share of MXN973.17 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Amgen and its competitors. Amgen's current Cyclically Adjusted Revenue per Share is MXN973.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amgen stock overvalued right now?
Based on GuruFocus' analysis, Amgen (MEX:AMG N) is currently considered Fairly Valued. The stock's GF Value™ is MXN6,234.06, compared to a current price of MXN6,349.00 — trading 1.8% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is MXN973.17. Amgen's overall GF Score™ is 86/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Amgen (MEX:AMG N), the current Cyclically Adjusted Revenue per Share is MXN973.17 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amgen (MEX:AMG N) Overvalued in 2026?

Based on GuruFocus' analysis, Amgen stock appears to be overvalued. The current stock price of MXN6,349.00 is trading 1.8% above its estimated GF Value™ of MXN6,234.06. GuruFocus considers Amgen to be Fairly Valued.

Key valuation signals for MEX:AMG N:

  • Cyclically Adjusted Revenue per Share: MXN973.17
  • GF Value™: MXN6,234.06 vs. price of MXN6,349.00 (1.8% above fair value)
  • GF Score™: 86/100 with 8 warning signs

No single metric tells the full story. See the MEX:AMG N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Amgen Business Description

Address One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
86GF Score

Get the complete analysis for MEX:AMG N

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN6,349.00
Price
MXN6,234.06
GF Value